Home Latest Articles
Latest Articles
  • Huiyu XU, Yaodong YAN, Ruizhe QI
    World Clinical Drug. 2025, 46(4): 393-400.
    Objective

    To explore and analyze the adverse drug event (ADE) signals of sacituzumab govitecan in the database of the Food and Drug Administration adverse event reporting system (FAERS) of the United States.

    Method

    Adverse event reports related to sacituzumab govitecan from the second quarter of 2020 to the first quarter of 2024 were selected from the United States FAERS database. The reporting odds ratio method in the ratio imbalance method in combination with the Bayesian confidence propagation neural network (BCPNN) method were used to conduct data mining and analysis.

    Result

    After screening, a total of 3 085 ADE reports were obtained. Among them, female patients accounted for a relatively large proportion (86.09%), and the age group was mainly 45~64 years old (25.35%). The reporting country was mainly the United States (34.20%). The outcome was mainly composed of mortality rate (26.65%) and hospitalization rate (28.75%). There were 145 positive signals related to ADE involving 26 systemic organ classifications.The frequency of occurrence of ADE signals was basically consistent with the instructions. The instructions do not mention serious adverse reactions such as hemorrhagic diarrhea, paralytic intestinal obstruction, large intestine perforation, febrile bone marrow aplasia and bone marrow failure, etc..

    Conclusion

    When doctors us sacituzumab govitecan in clinical practice, it is necessary to conduct an assessment for the patient's medication use. During the treatment period, new adverse reactions should be vigilant, and timely intervention should be carried out when abnormalities are detected.

  • Jiangfei GAO, Wanyi ZHENG, Jianming LIU, Yang ZHANG, Hualing SONG
    World Clinical Drug. 2025, 46(4): 401-406.
    Objective

    To systematically introduce how to calculate the 50% effective concentration (EC50) of drugs using the Probit module in SPSS27.0 based on clinical research data, tproviding a reference for clinical researchers.

    Methods

    Taking a set of clinical data as an example, this study elucidates the specific steps of calculating the EC50 of drugs using SPSS27.0 and interprets the main output results. Additionally, the EC50 obtained by this method are compared and validated with those calculated by GraphPad Prism9.5.

    Results

    The EC50 calculated and analyzed by SPSS software are consistent with those obtained by GraphPad Prism9.5. Moreover, SPSS27.0 features simple steps and quick operations.

    Conclusion

    SPSS27.0 can be used to calculate and analyze EC50, which is convenient and fast in operation and is an ideal choice for clinical researchers who are not specialized in statistics.

  • Lixin ZHANG, Yongli LIANG, Lutong REN, Yang LIU, Guleng Siri
    World Clinical Drug. 2025, 46(4): 407-410.
  • Xuan HU, Fan ZHAO, Bingzheng SHEN, Ke SU
    World Clinical Drug. 2025, 46(4): 411-415.

    Oxidative stress and inflammation are common factors that lead to the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), and methylbardoxolone is an agonist of antioxidant and anti-inflammatory factors such nuclear factor erythroid-related factor 2. It can increase the glomerular filtration rate (GFR) of patients with CKD. Methylbardoxolone has a good effect in increasing GFR. However, because it can increase the risk of cardiovascular events and proteinuria, and fails to improve the incidence of ESRD, it ultimately failed to become a therapeutic drug for CKD. This article reviewed the effects of methylbardoxolone in clinical trials of CKD drugs caused by multiple factors, aiming to provide a reference for its application.

  • Haipeng WU, Yuting CAO, Wei LIU, Lu ZHAO, Huan LIU
    World Clinical Drug. 2025, 46(4): 416-422.

    Refractory gout (RG) is an end-stage disease progression of gout involving multiple joints and repeated acute attacks. The typical clinical features include chronic gout stone formation, multifocal bone erosion and progressive loss of joint function, which finally progresses to erosive arthritis. Western medicine for RG focuses on the regulation of inflammatory response and the reestablishment of uric acid homeostasis, among which biologics and new targeted drugs have become an important research hotspot for breaking through the traditional therapy. Traditional Chinese medicine includes prescription and external treatment in RG management, which can help to realize the regulation of local inflammatory microenvironment. This article compared and analyzed the progress of RG treatment with traditional Chinese and western medicine in order to provide new ideas for clinical treatment.

  • Xingyun HOU, Weiqing GE, Chengjie KAN, Yue WANG, Wei TANG
    World Clinical Drug. 2025, 46(4): 423-428.
    Objective

    To explore the application effect of pharmaceutical follow-up in patients with hyperthyroidism based on intelligent pharmaceutical monitoring system.

    Methods

    A total of 200 patients with hyperthyroidism in the outpatient and inpatient departments of our hospital from September to December 2023 were selected, and they were divided into two levels according to the severity of the disease: hyperthyroidism and hyperthyroid-related eye disease, and 50 cases in each level were collected for the study group and control group, respectively. The control group received routine pharmaceutical care, and the study group added a monitoring system on the basis of the control group to follow up the patients. After 6 months of follow-up, the intervention effects of each level in the two groups were compared respectively before and after follow-up.

    Results

    There were statistically significant differences in medication adherence and emotional scales between the two-level study group and the control group (P<0.05). The incidence of adverse drug reactions in the study group was lower than that in the control group.

    Conclusion

    Compared with traditional pharmaceutical care, pharmaceutical follow-up based on pharmaceutical monitoring system can help improve medication compliance of patients with hyperthyroidism, reduce the risk of adverse reactions, and alleviate the psychological burden of the disease.

  • Li ZHOU, Xin CHEN, Xia CHEN
    World Clinical Drug. 2025, 46(3): 211-217.

    Chronic heart failure(CHF) is the ultimate outcome of various cardiovascular diseases. Heart, lung and kidney are closed related to the occurrence and development of CHF, so simultaneous treatment of heart, lung and kidney should be paid attention to. The following is specific treatment measures: supplementing the heart Qi, especially heart Yang Qi, ascending and dispersing the lung Qi, clearing the lung, supplementing kidney Yang Qi, removing stasis and improving water. Mahuang Fuzi Xixin decoction, Shenge powder are the typical decoctions in the treatment of CHF from heart, lung and kidney at the same time. This article reviewed the simultaneous treatment of heart, lung, and kidney in CHF, in order to provide reference for clinical application.

  • Jingyi CHEN, Xingwang LIANG, Xiaoying SONG, Xinyue XING, Jiajie XIE, Danfei LOU
    World Clinical Drug. 2025, 46(3): 218-223.

    Chronic heart failure(CHF) is a complex clinical syndrome caused by abnormal changes in cardiac structure and/or function resulting from various factors, which leads to impaired ventricular contraction and/or relaxation functions. In recent years, traditional Chinese medicine(TCM) has achieved remarkable results in the clinical diagnosis and treatment of CHF, particularly showing unique advantages in improving prognosis and quality of life. This article focused on major therapeutic approaches, including promoting blood circulation and removing stasis, tonifying Qi and promoting blood circulation, and nourishing Qi and Yin. It also discussed recent clinical research progress based on classic TCM formulas to explore the applications and development prospects of TCM in CHF treatment.

  • Jing LIANG, Chang LIU, Wei LI, Min CAO
    World Clinical Drug. 2025, 46(3): 224-229.

    Chronic heart failure(CHF) has a high incidence rate and a poor prognosis. It is the end-stage of heart disease caused by a variety of causes and poses a serious threat to human health. This article discussed the pattern differentiation and treatment of CHF from the perspectives of Treatise on Cold Damage and Synopsis of the Golden Chamber, highlighting the dialectical characteristics of "deficiency", "stasis", and "water" in CHF. Meanwhile, it summarized the treatment principles and methods, the rational theories and prescriptions based on the comorbidities of CHF, in order to offer novel perspectives for clinical management.

  • Xiaomei ZHANG, Ying A, Haiyan QU
    World Clinical Drug. 2025, 46(3): 230-235.
    Objective

    To investigate the clinical efficacy and impact on liver function of bicyclol combined with ornithine aspartate granules in patients with decompensated cirrhosis(DCC).

    Methods

    A total of 80 DCC patients diagnosed in our hospital from October 2021 to December 2022 were selected and divided into control group and study group by simple randomization method, with 40 patients in each group. The control group was treated with dicyclol, and the study group was treated with dicyclol combined with ornithine aspartate granules. Both groups were treated continuously for 3 weeks. The clinical effect, liver function index, liver fibrosis index, serum levels of inflammatory cytokines, T lymphocytes and the occurrence of adverse reactions were compared between two groups after treatment.

    Results

    After treatment, the total effective rate of the study group was higher than of the control group(92.50% vs. 75.00%, P<0.05). Total bilirubin, aspartate aminotransferase, alanine aminotransferase, interleukin(IL)-2, IL-6, tumor necrosis factor-α, C-reactive protein, laminin, and hyaluronic acid decreased in both groups compared with those before treatment, and the study group was lower than the control group(P<0.05). The levels of CD3+, CD4+/CD8+ and CD4+ in both groups were significantly higher than before treatment, and the study group was higher than the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the study group and the control group(5.00% vs. 12.50%,P>0.05).

    Conclusion

    In the treatment of DCC patients, dicyclol combined with ornithine aspartate granules can effectively improve clinical symptoms, improve clinical efficacy, improve liver function and immune capacity, reduce inflammatory response, and reduce the degree of cirrhosis.

News